Jon Edwards, PhD, Appointed Partner
Naarden, The Netherlands – 1 October 2025 - Forbion, a leading life sciences venture capital firm with deep expertise in Europe, today announces the appointment of Jon Edwards, PhD, as Partner at its Boston office. Jon will leverage his extensive industry network and strategic expertise to source new opportunities and support existing portfolio companies, with a particular focus on the U.S. and Canadian markets.
Jon brings significant experience in building and scaling biotech companies. He previously served as Managing Partner at Bioqube Ventures, Managing Director at Red Tree Venture Capital, and was a Partner at Medicxi in London. Over his career he has led investments spanning company formation, syndicated deals, and late-stage crossover/IPO financings. Notable successes include Bicara Therapeutics (NASDAQ: BCAX), Impact Biomedicines (acquired by Celgene), Synthorx (acquired by Sanofi), Phathom Pharmaceuticals (NASDAQ: PHAT), and Checkmate Pharmaceuticals (acquired by Regeneron). Jon earned a Ph.D. in Biochemistry and Biophysics from the University of North Carolina, Chapel Hill, and completed postdoctoral research at MIT.
“Our growing Boston team strengthens Forbion’s ability to support entrepreneurs and portfolio companies across our trans-Atlantic footprint. Jon’s track record, spanning multiple major exits and Nasdaq IPOs, speaks for itself. We are delighted to welcome him to the partnership.”
Martien van Osch
Managing Partner
“I’m thrilled to join Forbion at such an exciting time. The company's track record of supporting transformational science makes this a unique opportunity to partner with outstanding entrepreneurs and help build the next generation of leading biotech companies. I couldn't be more excited to join such a high calibre group of colleagues. Forbion has a fantastic reputation and I look forward to advancing our U.S. efforts with them."
Jon Edwards, PhD
Partner
In Boston, Jon will work closely with co-founder and Managing Partner, Martien van Osch, and Principal, Regina Salvat, PhD. Established in June 2024, Forbion’s Boston office serves as a hub for Forbion’s US operations, enabling close collaboration with portfolio companies and access to a vibrant biotech ecosystem.
**ENDS**
About Forbion
Forbion is a leading global venture capital firm with deep expertise in Europe and offices in Naarden, the Netherlands, Munich, Germany, and Boston, USA. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies covering all stages of (bio)pharmaceutical drug development. In addition to its human health focus, Forbion also invests in planetary health solutions through its BioEconomy strategy. The firm’s team of over 30 investment professionals has a strong track record, with more than 130 investments across 11 funds, resulting in numerous approved therapies and successful exits. Forbion is a signatory to the UN Principles for Responsible Investment and operates a joint venture with BGV for seed and early-stage investments in the Benelux and Germany regions.
